AstraZeneca offers some detail on China probe, reaffirms commitment to that market

LON­DON — As­traZeneca on Thurs­day pro­vid­ed in­sight on an on­go­ing Chi­na probe in­to the com­pa­ny con­cern­ing al­leged il­le­gal drug im­ports, giv­ing in­vestors and an­a­lysts some re­as­sur­ance …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.